The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation

This publication has 26 references indexed in Scilit:

• Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice
  Neuroscience Letters, 1997
• The Neuronal Nitric Oxide Synthase Inhibitor 7-Nitroindazole Also Inhibits the Monoamine Oxidase-B-Catalyzed Oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  Chemical Research in Toxicology, 1997
• Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study
  European Journal of Pharmacology, 1995
• Riluzole and experimental parkinsonism
  NeuroReport, 1994
• Riluzole and experimental parkinsonism
  NeuroReport, 1994
• A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
  New England Journal of Medicine, 1994
• Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes
  European Journal of Pharmacology, 1993
• Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo
  Neuroscience Letters, 1992
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
  Proceedings of the National Academy of Sciences, 1983
• Chronic parkinsonism secondary to intravenous injection of meperidine analogues
  Psychiatry Research, 1979